Canada - English - Health Canada

sterimax inc - thiotepa - powder for solution - 100mg - thiotepa 100mg

Canada - English - Health Canada

hikma canada limited - thiotepa - powder for solution - 15mg - thiotepa 15mg

Canada - English - Health Canada

hikma canada limited - thiotepa - powder for solution - 100mg - thiotepa 100mg

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - thiotepa (unii: 905z5w3gkh) (thiotepa - unii:905z5w3gkh) - thiotepa for injection has been tried with varying results in the palliation of a wide variety of neoplastic diseases. however, the most consistent results have been seen in the following tumors: - adenocarcinoma of the breast. - adenocarcinoma of the ovary. - for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. - for the treatment of superficial papillary carcinoma of the urinary bladder. while now largely superseded by other treatments, thiotepa for injection has been effective against other lymphomas, such as lymphosarcoma and hodgkin's disease. thiotepa is contraindicated in patients with a known hypersensitivity (allergy) to this preparation. therapy is probably contraindicated in cases of existing hepatic, renal, or bone-marrow damage. however, if the need outweighs the risk in such patients, thiotepa may be used in low dosage, and accompanied by hepatic, renal and hemopoietic function tests.

United States - English - NLM (National Library of Medicine)

dr.reddy's laboratories inc., - thiotepa (unii: 905z5w3gkh) (thiotepa - unii:905z5w3gkh) - thiotepa for injection, usp has been tried with varying results in the palliation of a wide variety of neoplastic diseases. however, the most consistent results have been seen in the following tumors: 1. adenocarcinoma of the breast. 2. adenocarcinoma of the ovary. 3. for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. 4. for the treatment of superficial papillary carcinoma of the urinary bladder. while now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and hodgkin’s disease. thiotepa is contraindicated in patients with a known hypersensitivity (allergy) to this preparation. therapy is probably contraindicated in cases of existing hepatic, renal, or bone-marrow damage. however, if the need outweighs the risk in such patients, thiotepa may be used in low dosage, and accompanied by hepatic, renal and hemopoietic function tests.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - thiotepa (unii: 905z5w3gkh) (thiotepa - unii:905z5w3gkh) - thiotepa for injection, usp has been tried with varying results in the palliation of a wide variety of neoplastic diseases. however, the most consistent results have been seen in the following tumors: - 1.adenocarcinoma of the breast. - 2.adenocarcinoma of the ovary. - 3.for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. - 4.for the treatment of superficial papillary carcinoma of the urinary bladder. while now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and hodgkin's disease. thiotepa is contraindicated in patients with a known hypersensitivity (allergy) to this preparation. therapy is probably contraindicated in cases of existing hepatic, renal, or bone-marrow damage. however, if the need outweighs the risk in such patients, thiotepa may be used in low dosage, and accompanied by hepatic, renal and hemopoietic function tests.

United States - English - NLM (National Library of Medicine)

sti pharma llc - thiotepa (unii: 905z5w3gkh) (thiotepa - unii:905z5w3gkh) - thiotepa for injection, usp has been tried with varying results in the palliation of a wide variety of neoplastic diseases. however, the most consistent results have been seen in the following tumors: 1. adenocarcinoma of the breast. 2. adenocarcinoma of the ovary. 3. for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. 4. for the treatment of superficial papillary carcinoma of the urinary bladder. while now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and hodgkin's disease. thiotepa is contraindicated in patients with a known hypersensitivity (allergy) to this preparation. therapy is probably contraindicated in cases of existing hepatic, renal, or bone-marrow damage. however, if the need outweighs the risk in such patients, thiotepa may be used in low dosage, and a

United States - English - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - thiotepa (unii: 905z5w3gkh) (thiotepa - unii:905z5w3gkh) - thiotepa for injection, usp has been tried with varying results in the palliation of a wide variety of neoplastic diseases. however, the most consistent results have been seen in the following tumors: - 1. adenocarcinoma of the breast. - 2. adenocarcinoma of the ovary. - 3. for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. - 4. for the treatment of superficial papillary carcinoma of the urinary bladder. while now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and hodgkin's disease. thiotepa is contraindicated in patients with a known hypersensitivity (allergy) to this preparation. therapy is probably contraindicated in cases of existing hepatic, renal, or bone-marrow damage. however, if the need outweighs the risk in such patients, thiotepa may be used in low dosage, and accompanied by hepatic, renal and hemopoietic function tests.

United States - English - NLM (National Library of Medicine)

dr.reddy's laboratories inc., - thiotepa (unii: 905z5w3gkh) (thiotepa - unii:905z5w3gkh) - thiotepa for injection is indicated for treatment of adenocarcinoma of the breast or ovary. thiotepa for injection is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. thiotepa for injection is indicated for treatment of superficial papillary carcinoma of the urinary bladder. pediatric use information is approved for adienne sa' s tepadina (thiotepa) for injection. however, due to adienne sa's marketing exclusivity rights, the drug product is not labeled with that information. thiotepa is contraindicated in: - patients with severe hypersensitivity to thiotepa [see warnings and precautions (5.2)] - concomitant use with live or attenuated vaccines [see warnings and precautions (5.4)] risk summary thiotepa can cause fetal harm when administered to a pregnant woman based on findings from animals and the drug’s mechanism of action [see clinical pharmacology (12.1)] . limited available data with thiotepa use in pregnant women are ins

United States - English - NLM (National Library of Medicine)

msn laboratories private limited - thiotepa (unii: 905z5w3gkh) (thiotepa - unii:905z5w3gkh) - thiotepa for injection is indicated for treatment of adenocarcinoma of the breast or ovary. thiotepa for injection is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. thiotepa for injection is indicated for treatment of superficial papillary carcinoma of the urinary bladder. pediatric use information is approved for adienne sa 's tepadina (thiotepa) for injection. however, due to adienne sa 's marketing exclusivity rights, the drug product is not labeled with that information. thiotepa for injection is contraindicated in: - patients with severe hypersensitivity to thiotepa [see warnings and precautions (5.2)] - concomitant use with live or attenuated vaccines [see warnings and precautions (5.4)] risk summary thiotepa can cause fetal harm when administered to a pregnant woman based on findings from animals and the drug’s mechanism of action [see clinical pharmacology (12.1)] . limited available data with thiotepa use in pr